Edition:
United States

Ocular Therapeutix Inc (OCUL.OQ)

OCUL.OQ on NASDAQ Stock Exchange Global Market

4.22USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
89,428
52-wk High
$11.79
52-wk Low
$3.30

Select another date:

Tue, Nov 7 2017

BRIEF-Ocular Therapeutix posts Q3 loss per share $0.54

* Ocular Therapeutix reports third quarter 2017 financial results and provides corporate update

BRIEF-Ocular Therapeutix appoints Donald Notman as chief financial officer

* Ocular Therapeutix appoints Donald Notman as chief financial officer

BRIEF-Ocular Therapeutix Q2 loss per share $0.64

* Ocular therapeutix™ reports second quarter 2017 financial results and provides corporate update

BRIEF-Ocular hires Daniel Bollag for pharmacovigilance and quality

* Ocular Therapeutix appoints Daniel Bollag, PH.D., as senior vice president, regulatory affairs, pharmacovigilance and quality Source text for Eikon: Further company coverage:

BRIEF-Ocular Therapeutix to eliminate 26 positions across organization

* Ocular Therapeutix says on july 31, board of directors approved a strategic restructuring to eliminate a portion of company's workforce - sec filing

BRIEF-Ocular Therapeutix submits amendment to potentially extend review for Dextenza NDA

* Ocular Therapeutix submits amendment to potentially extend review for Dextenza New Drug Application (NDA)

BRIEF-Ocular Therapeutix announces executive transition plans

* Says Antony Mattessich to assume CEO role in September 2017

Select another date: